Other Events ·
Azitra suspends ATM equity program after selling 1,000 shares for $126
AZTRAzitra, Inc.
Azitra has decided not to utilize its at-the-market offering (ATM) program for the foreseeable future. From September 28 through October 26, 2026, the company sold an aggregate of 1,000 shares under the ATM program for gross proceeds of approximately $126. Management cited current capital resources, anticipated operational milestones, recent trading price, and dilutive effects as reasons for suspending sales. The company may resume sales or pursue other financing transactions at its discretion. Azitra is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high-value cosmetic proteins.